logo-loader
NASDAQ:PHVS

Pharvaris

Receive alerts
Market:
NASDAQ
Price
31.66 USD
Day Change
0.35%
Market Cap:
$2.24 b
52 weeks high
43.25
52 weeks low
23.23

In brief

Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target¹⁻³ with novel, oral small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.

Pharvaris is committed to a strong collaboration, closely partnering with patient organizations as well as experts in the HAE community. Throughout the company, we aim to build trust and ongoing dialogue with all members of the community working with and for those with HAE to support people and their families to build knowledge, awareness, education and further HAE research.